Allgaier H P, Deibert P, Becker G, Blum H E
Abteilung Innere Medizin II (Gastroenterologie, Hepatologie und Endokrinologie), Medizinische Universitätsklinik Freiburg.
Praxis (Bern 1994). 1998 Oct 28;87(44):1466-70.
The therapeutic modalities in patients with hepatocellular carcinoma (HCC) depend on the number, size and location of the lesions as well as the stage of the underlying liver disease and the physical condition of the patients. In patients with small and solitary lesions resection, liver resection and in selected cases liver transplantation can be curative. In more advanced stages of the disease with larger or multiple lesions PEI and/or transarterial chemotherapy with or without embolisation (TACE or TAC) can slow the progression of the disease. In disseminated disease, a radio-therapeutic approach can be taken in selected cases. The therapeutic strategy in patients with HCCs has to be individualized, frequently using a combination of therapeutic modalities. Different from the earlier unfavourable prognosis, today for most HCC patients a therapeutic strategy can be offered that results in a prolongation of life and in some cases even cure.
肝细胞癌（HCC）患者的治疗方式取决于病变的数量、大小和位置，以及潜在肝脏疾病的阶段和患者的身体状况。对于小的孤立性病变患者，肝切除以及在某些情况下肝移植可能治愈疾病。在疾病的更晚期，病变较大或为多发时，经皮乙醇注射（PEI）和/或伴有或不伴有栓塞的经动脉化疗（TACE或TAC）可以减缓疾病进展。在播散性疾病中，某些情况下可采用放射治疗方法。HCC患者的治疗策略必须个体化，经常使用多种治疗方式的组合。与早期不利的预后不同，如今对于大多数HCC患者可以提供一种治疗策略，从而延长生命，在某些情况下甚至可以治愈。
